ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average – What’s Next?

ImmuCell Corporation (NASDAQ:ICCC)’s share price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.08 and traded as high as $6.59. ImmuCell shares last traded at $6.24, with a volume of 21,559 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of ImmuCell in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, ImmuCell presently has an average rating of “Sell”.

ImmuCell Trading Down 5.5%

The business’s 50-day simple moving average is $6.26 and its two-hundred day simple moving average is $6.08. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $56.45 million, a PE ratio of 24.00 and a beta of 0.30.

Hedge Funds Weigh In On ImmuCell

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after buying an additional 2,907 shares in the last quarter. Mesirow Financial Investment Management Inc. raised its holdings in ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after acquiring an additional 24,303 shares in the last quarter. Finally, Steadtrust LLC boosted its stake in ImmuCell by 79.1% during the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 25,070 shares during the last quarter. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.